Hemato-Oncology Daily Report: 01/25/2024
Chronic Lymphocytic Leukemia
A phase 3, multicenter, randomized, controlled, open-label study investigated the effect of ibrutinib-venetoclax in 523 patients with untreated CLL and found that disease progression or death occurred less frequently in the ibrutinib-venetoclax group compared to the fludarabine-cyclophosphamide-rituximab group (hazard ratio, 0.13), with 58.0% of patients in the ibrutinib-venetoclax group stopping therapy due to undetectable MRD at 3 years (1).
Reference
Munir T, Cairns DA, Bloor A, Allsup D, Cwynarski K, Pettitt A, Paneesha S, Fox CP, Eyre TA, Forconi F, Elmusharaf N, Kennedy B, Gribben J, Pemberton N, Sheehy O, Preston G, Schuh A, Walewska R, Duley L, Howard D, Hockaday A, Jackson S, Greatorex N, Girvan S, Bell S, Brown JM, Webster N, Dalal S, de Tute R, Rawstron A, Patten PEM, Hillmen P; National Cancer Research Institute Chronic Lymphocytic Leukemia Subgroup. Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. N Engl J Med. 2024 Jan 25;390(4):326-337. doi: 10.1056/NEJMoa2310063. Epub 2023 Dec 10. PMID: 38078508.
Multiple Myeloma
Multiple Myeloma A phase 3 trial investigated the effect of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (D-VRd) in 709 transplantation-eligible patients with newly diagnosed multiple myeloma and found that the D-VRd group had a significantly lower risk of disease progression or death compared to the VRd group (1). The estimated 48-month progression-free survival rate was 84.3% in the D-VRd group versus 67.7% in the VRd group (hazard ratio for disease progression or death, 0.42; P<0.001). The D-VRd group also had a higher percentage of patients achieving a complete response or better (87.9% vs. 70.1%, P<0.001) and MRD-negative status (75.2% vs. 47.5%, P<0.001). Grade 3 or 4 adverse events were common in both groups, with neutropenia and thrombocytopenia being the most common. The study was funded by the European Myeloma Network in collaboration with Janssen Research and Development; PERSEUS ClinicalTrials.gov number, NCT03710603; EudraCT number, 2018-002992-16.
Reference
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P; PERSEUS Trial Investigators. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12. PMID: 38084760.